nodes	percent_of_prediction	percent_of_DWPC	metapath
Paroxetine—CYP2C8—Medroxyprogesterone Acetate—uterine cancer	0.106	0.197	CbGbCtD
Paroxetine—CYP2C9—Medroxyprogesterone Acetate—uterine cancer	0.0738	0.137	CbGbCtD
Paroxetine—CYP2C8—Progesterone—uterine cancer	0.0701	0.13	CbGbCtD
Paroxetine—CYP2C9—Progesterone—uterine cancer	0.0489	0.091	CbGbCtD
Paroxetine—ABCB1—Progesterone—uterine cancer	0.0474	0.0883	CbGbCtD
Paroxetine—CYP2D6—Progesterone—uterine cancer	0.0447	0.0832	CbGbCtD
Paroxetine—ABCB1—Dactinomycin—uterine cancer	0.0376	0.07	CbGbCtD
Paroxetine—CYP2C8—Etoposide—uterine cancer	0.0314	0.0584	CbGbCtD
Paroxetine—CYP2B6—Doxorubicin—uterine cancer	0.0282	0.0526	CbGbCtD
Paroxetine—ABCB1—Etoposide—uterine cancer	0.0212	0.0395	CbGbCtD
Paroxetine—ABCB1—Doxorubicin—uterine cancer	0.0145	0.0269	CbGbCtD
Paroxetine—CHRM3—ureter—uterine cancer	0.014	0.22	CbGeAlD
Paroxetine—CYP2D6—Doxorubicin—uterine cancer	0.0136	0.0254	CbGbCtD
Paroxetine—CHRM3—muscle of abdomen—uterine cancer	0.01	0.159	CbGeAlD
Paroxetine—TACR1—smooth muscle tissue—uterine cancer	0.0028	0.0443	CbGeAlD
Paroxetine—CHRM3—exocrine gland—uterine cancer	0.00275	0.0434	CbGeAlD
Paroxetine—TACR1—renal system—uterine cancer	0.0027	0.0426	CbGeAlD
Paroxetine—TACR1—female reproductive system—uterine cancer	0.00216	0.0342	CbGeAlD
Paroxetine—CHRM5—epithelium—uterine cancer	0.00214	0.0338	CbGeAlD
Paroxetine—HTR2A—artery—uterine cancer	0.00187	0.0296	CbGeAlD
Paroxetine—TACR1—lymph node—uterine cancer	0.00126	0.02	CbGeAlD
Paroxetine—CHRM3—smooth muscle tissue—uterine cancer	0.00115	0.0182	CbGeAlD
Paroxetine—SLC6A2—decidua—uterine cancer	0.00112	0.0176	CbGeAlD
Paroxetine—CHRM3—renal system—uterine cancer	0.00111	0.0175	CbGeAlD
Paroxetine—SLC6A4—female reproductive system—uterine cancer	0.000996	0.0157	CbGeAlD
Paroxetine—CHRM1—female reproductive system—uterine cancer	0.000993	0.0157	CbGeAlD
Paroxetine—CYP2C8—renal system—uterine cancer	0.0009	0.0142	CbGeAlD
Paroxetine—CHRM3—female reproductive system—uterine cancer	0.000888	0.014	CbGeAlD
Paroxetine—SLC6A2—female reproductive system—uterine cancer	0.000877	0.0139	CbGeAlD
Paroxetine—CYP2C8—endometrium—uterine cancer	0.00087	0.0137	CbGeAlD
Paroxetine—CHRM3—female gonad—uterine cancer	0.000808	0.0128	CbGeAlD
Paroxetine—CYP2B6—renal system—uterine cancer	0.000807	0.0128	CbGeAlD
Paroxetine—CYP2C8—female reproductive system—uterine cancer	0.000721	0.0114	CbGeAlD
Paroxetine—HTR2A—epithelium—uterine cancer	0.00071	0.0112	CbGeAlD
Paroxetine—HTR2A—smooth muscle tissue—uterine cancer	0.000684	0.0108	CbGeAlD
Paroxetine—HTR2A—renal system—uterine cancer	0.000658	0.0104	CbGeAlD
Paroxetine—CYP2C8—vagina—uterine cancer	0.000652	0.0103	CbGeAlD
Paroxetine—CYP2B6—female reproductive system—uterine cancer	0.000646	0.0102	CbGeAlD
Paroxetine—CYP2C9—female reproductive system—uterine cancer	0.00064	0.0101	CbGeAlD
Paroxetine—CYP2D6—renal system—uterine cancer	0.0006	0.00948	CbGeAlD
Paroxetine—ABCB1—myometrium—uterine cancer	0.000593	0.00936	CbGeAlD
Paroxetine—CYP2B6—vagina—uterine cancer	0.000585	0.00924	CbGeAlD
Paroxetine—HTR2A—female reproductive system—uterine cancer	0.000527	0.00833	CbGeAlD
Paroxetine—SLC6A2—lymph node—uterine cancer	0.000513	0.00811	CbGeAlD
Paroxetine—CYP2D6—female reproductive system—uterine cancer	0.00048	0.00759	CbGeAlD
Paroxetine—HTR2A—vagina—uterine cancer	0.000477	0.00753	CbGeAlD
Paroxetine—ABCB1—epithelium—uterine cancer	0.000465	0.00735	CbGeAlD
Paroxetine—ABCB1—uterine cervix—uterine cancer	0.000461	0.00729	CbGeAlD
Paroxetine—ABCB1—decidua—uterine cancer	0.000439	0.00694	CbGeAlD
Paroxetine—CYP2D6—female gonad—uterine cancer	0.000437	0.00691	CbGeAlD
Paroxetine—ABCB1—renal system—uterine cancer	0.000431	0.00682	CbGeAlD
Paroxetine—ABCB1—endometrium—uterine cancer	0.000417	0.00659	CbGeAlD
Paroxetine—ABCB1—mammalian vulva—uterine cancer	0.000403	0.00637	CbGeAlD
Paroxetine—ABCB1—uterus—uterine cancer	0.000384	0.00607	CbGeAlD
Paroxetine—ABCB1—female reproductive system—uterine cancer	0.000346	0.00546	CbGeAlD
Paroxetine—ABCB1—female gonad—uterine cancer	0.000314	0.00497	CbGeAlD
Paroxetine—ABCB1—vagina—uterine cancer	0.000313	0.00494	CbGeAlD
Paroxetine—ABCB1—lymph node—uterine cancer	0.000202	0.00319	CbGeAlD
Paroxetine—Muscular weakness—Doxorubicin—uterine cancer	0.000115	0.000291	CcSEcCtD
Paroxetine—Alanine aminotransferase increased—Doxorubicin—uterine cancer	0.000115	0.000291	CcSEcCtD
Paroxetine—Dysuria—Epirubicin—uterine cancer	0.000114	0.000288	CcSEcCtD
Paroxetine—Influenza—Doxorubicin—uterine cancer	0.000113	0.000285	CcSEcCtD
Paroxetine—Asthma—Doxorubicin—uterine cancer	0.000113	0.000285	CcSEcCtD
Paroxetine—Dysphagia—Doxorubicin—uterine cancer	0.000113	0.000285	CcSEcCtD
Paroxetine—Pollakiuria—Epirubicin—uterine cancer	0.000113	0.000284	CcSEcCtD
Paroxetine—Eosinophilia—Doxorubicin—uterine cancer	0.000112	0.000282	CcSEcCtD
Paroxetine—Photosensitivity reaction—Epirubicin—uterine cancer	0.000111	0.000281	CcSEcCtD
Paroxetine—Paraesthesia—Etoposide—uterine cancer	0.000111	0.00028	CcSEcCtD
Paroxetine—Weight increased—Epirubicin—uterine cancer	0.000111	0.00028	CcSEcCtD
Paroxetine—Pancreatitis—Doxorubicin—uterine cancer	0.000111	0.000279	CcSEcCtD
Paroxetine—Weight decreased—Epirubicin—uterine cancer	0.00011	0.000278	CcSEcCtD
Paroxetine—Dyspnoea—Etoposide—uterine cancer	0.00011	0.000278	CcSEcCtD
Paroxetine—Hyperglycaemia—Epirubicin—uterine cancer	0.00011	0.000278	CcSEcCtD
Paroxetine—Somnolence—Etoposide—uterine cancer	0.00011	0.000278	CcSEcCtD
Paroxetine—Angina pectoris—Doxorubicin—uterine cancer	0.00011	0.000277	CcSEcCtD
Paroxetine—Pneumonia—Epirubicin—uterine cancer	0.000109	0.000276	CcSEcCtD
Paroxetine—Drowsiness—Epirubicin—uterine cancer	0.000109	0.000274	CcSEcCtD
Paroxetine—Vomiting—Dactinomycin—uterine cancer	0.000109	0.000274	CcSEcCtD
Paroxetine—Bronchitis—Doxorubicin—uterine cancer	0.000109	0.000274	CcSEcCtD
Paroxetine—Stevens-Johnson syndrome—Epirubicin—uterine cancer	0.000108	0.000272	CcSEcCtD
Paroxetine—Rash—Dactinomycin—uterine cancer	0.000108	0.000272	CcSEcCtD
Paroxetine—Decreased appetite—Etoposide—uterine cancer	0.000108	0.000271	CcSEcCtD
Paroxetine—Pancytopenia—Doxorubicin—uterine cancer	0.000107	0.00027	CcSEcCtD
Paroxetine—Gastrointestinal disorder—Etoposide—uterine cancer	0.000107	0.00027	CcSEcCtD
Paroxetine—Fatigue—Etoposide—uterine cancer	0.000107	0.000269	CcSEcCtD
Paroxetine—Neuropathy peripheral—Epirubicin—uterine cancer	0.000107	0.000269	CcSEcCtD
Paroxetine—Stomatitis—Epirubicin—uterine cancer	0.000106	0.000267	CcSEcCtD
Paroxetine—Jaundice—Epirubicin—uterine cancer	0.000106	0.000267	CcSEcCtD
Paroxetine—Constipation—Etoposide—uterine cancer	0.000106	0.000267	CcSEcCtD
Paroxetine—Pain—Etoposide—uterine cancer	0.000106	0.000267	CcSEcCtD
Paroxetine—Urinary tract infection—Epirubicin—uterine cancer	0.000106	0.000267	CcSEcCtD
Paroxetine—Conjunctivitis—Epirubicin—uterine cancer	0.000106	0.000267	CcSEcCtD
Paroxetine—Dysuria—Doxorubicin—uterine cancer	0.000106	0.000266	CcSEcCtD
Paroxetine—Sweating—Epirubicin—uterine cancer	0.000104	0.000263	CcSEcCtD
Paroxetine—Pollakiuria—Doxorubicin—uterine cancer	0.000104	0.000263	CcSEcCtD
Paroxetine—Haematuria—Epirubicin—uterine cancer	0.000104	0.000262	CcSEcCtD
Paroxetine—Photosensitivity reaction—Doxorubicin—uterine cancer	0.000103	0.00026	CcSEcCtD
Paroxetine—Hepatobiliary disease—Epirubicin—uterine cancer	0.000103	0.00026	CcSEcCtD
Paroxetine—Weight increased—Doxorubicin—uterine cancer	0.000103	0.000259	CcSEcCtD
Paroxetine—Epistaxis—Epirubicin—uterine cancer	0.000103	0.000259	CcSEcCtD
Paroxetine—Weight decreased—Doxorubicin—uterine cancer	0.000102	0.000258	CcSEcCtD
Paroxetine—Sinusitis—Epirubicin—uterine cancer	0.000102	0.000257	CcSEcCtD
Paroxetine—Feeling abnormal—Etoposide—uterine cancer	0.000102	0.000257	CcSEcCtD
Paroxetine—Hyperglycaemia—Doxorubicin—uterine cancer	0.000102	0.000257	CcSEcCtD
Paroxetine—Nausea—Dactinomycin—uterine cancer	0.000102	0.000256	CcSEcCtD
Paroxetine—Agranulocytosis—Epirubicin—uterine cancer	0.000102	0.000256	CcSEcCtD
Paroxetine—Pneumonia—Doxorubicin—uterine cancer	0.000101	0.000255	CcSEcCtD
Paroxetine—Gastrointestinal pain—Etoposide—uterine cancer	0.000101	0.000255	CcSEcCtD
Paroxetine—Drowsiness—Doxorubicin—uterine cancer	0.000101	0.000254	CcSEcCtD
Paroxetine—Stevens-Johnson syndrome—Doxorubicin—uterine cancer	9.98e-05	0.000252	CcSEcCtD
Paroxetine—Bradycardia—Epirubicin—uterine cancer	9.94e-05	0.000251	CcSEcCtD
Paroxetine—Neuropathy peripheral—Doxorubicin—uterine cancer	9.87e-05	0.000249	CcSEcCtD
Paroxetine—Urticaria—Etoposide—uterine cancer	9.83e-05	0.000248	CcSEcCtD
Paroxetine—Haemoglobin—Epirubicin—uterine cancer	9.81e-05	0.000248	CcSEcCtD
Paroxetine—Jaundice—Doxorubicin—uterine cancer	9.81e-05	0.000247	CcSEcCtD
Paroxetine—Stomatitis—Doxorubicin—uterine cancer	9.81e-05	0.000247	CcSEcCtD
Paroxetine—Rhinitis—Epirubicin—uterine cancer	9.79e-05	0.000247	CcSEcCtD
Paroxetine—Body temperature increased—Etoposide—uterine cancer	9.78e-05	0.000247	CcSEcCtD
Paroxetine—Abdominal pain—Etoposide—uterine cancer	9.78e-05	0.000247	CcSEcCtD
Paroxetine—Urinary tract infection—Doxorubicin—uterine cancer	9.78e-05	0.000247	CcSEcCtD
Paroxetine—Conjunctivitis—Doxorubicin—uterine cancer	9.78e-05	0.000247	CcSEcCtD
Paroxetine—Haemorrhage—Epirubicin—uterine cancer	9.76e-05	0.000246	CcSEcCtD
Paroxetine—Hepatitis—Epirubicin—uterine cancer	9.76e-05	0.000246	CcSEcCtD
Paroxetine—Hypoaesthesia—Epirubicin—uterine cancer	9.72e-05	0.000245	CcSEcCtD
Paroxetine—Pharyngitis—Epirubicin—uterine cancer	9.69e-05	0.000244	CcSEcCtD
Paroxetine—Sweating—Doxorubicin—uterine cancer	9.65e-05	0.000243	CcSEcCtD
Paroxetine—Oedema peripheral—Epirubicin—uterine cancer	9.62e-05	0.000243	CcSEcCtD
Paroxetine—Haematuria—Doxorubicin—uterine cancer	9.6e-05	0.000242	CcSEcCtD
Paroxetine—Connective tissue disorder—Epirubicin—uterine cancer	9.6e-05	0.000242	CcSEcCtD
Paroxetine—Hepatobiliary disease—Doxorubicin—uterine cancer	9.52e-05	0.00024	CcSEcCtD
Paroxetine—Epistaxis—Doxorubicin—uterine cancer	9.49e-05	0.000239	CcSEcCtD
Paroxetine—Sinusitis—Doxorubicin—uterine cancer	9.44e-05	0.000238	CcSEcCtD
Paroxetine—Visual impairment—Epirubicin—uterine cancer	9.41e-05	0.000237	CcSEcCtD
Paroxetine—Agranulocytosis—Doxorubicin—uterine cancer	9.39e-05	0.000237	CcSEcCtD
Paroxetine—Erythema multiforme—Epirubicin—uterine cancer	9.23e-05	0.000233	CcSEcCtD
Paroxetine—Bradycardia—Doxorubicin—uterine cancer	9.2e-05	0.000232	CcSEcCtD
Paroxetine—Eye disorder—Epirubicin—uterine cancer	9.12e-05	0.00023	CcSEcCtD
Paroxetine—Hypersensitivity—Etoposide—uterine cancer	9.12e-05	0.00023	CcSEcCtD
Paroxetine—Tinnitus—Epirubicin—uterine cancer	9.1e-05	0.00023	CcSEcCtD
Paroxetine—Haemoglobin—Doxorubicin—uterine cancer	9.08e-05	0.000229	CcSEcCtD
Paroxetine—Flushing—Epirubicin—uterine cancer	9.06e-05	0.000229	CcSEcCtD
Paroxetine—Cardiac disorder—Epirubicin—uterine cancer	9.06e-05	0.000229	CcSEcCtD
Paroxetine—Rhinitis—Doxorubicin—uterine cancer	9.06e-05	0.000229	CcSEcCtD
Paroxetine—Hepatitis—Doxorubicin—uterine cancer	9.03e-05	0.000228	CcSEcCtD
Paroxetine—Haemorrhage—Doxorubicin—uterine cancer	9.03e-05	0.000228	CcSEcCtD
Paroxetine—Hypoaesthesia—Doxorubicin—uterine cancer	8.99e-05	0.000227	CcSEcCtD
Paroxetine—Pharyngitis—Doxorubicin—uterine cancer	8.97e-05	0.000226	CcSEcCtD
Paroxetine—Oedema peripheral—Doxorubicin—uterine cancer	8.9e-05	0.000225	CcSEcCtD
Paroxetine—Asthenia—Etoposide—uterine cancer	8.88e-05	0.000224	CcSEcCtD
Paroxetine—Connective tissue disorder—Doxorubicin—uterine cancer	8.88e-05	0.000224	CcSEcCtD
Paroxetine—Angiopathy—Epirubicin—uterine cancer	8.86e-05	0.000223	CcSEcCtD
Paroxetine—Immune system disorder—Epirubicin—uterine cancer	8.82e-05	0.000222	CcSEcCtD
Paroxetine—Mediastinal disorder—Epirubicin—uterine cancer	8.8e-05	0.000222	CcSEcCtD
Paroxetine—Chills—Epirubicin—uterine cancer	8.76e-05	0.000221	CcSEcCtD
Paroxetine—Pruritus—Etoposide—uterine cancer	8.76e-05	0.000221	CcSEcCtD
Paroxetine—Arrhythmia—Epirubicin—uterine cancer	8.72e-05	0.00022	CcSEcCtD
Paroxetine—Visual impairment—Doxorubicin—uterine cancer	8.71e-05	0.00022	CcSEcCtD
Paroxetine—Alopecia—Epirubicin—uterine cancer	8.63e-05	0.000218	CcSEcCtD
Paroxetine—Mental disorder—Epirubicin—uterine cancer	8.55e-05	0.000216	CcSEcCtD
Paroxetine—Erythema multiforme—Doxorubicin—uterine cancer	8.54e-05	0.000216	CcSEcCtD
Paroxetine—Erythema—Epirubicin—uterine cancer	8.5e-05	0.000214	CcSEcCtD
Paroxetine—Malnutrition—Epirubicin—uterine cancer	8.5e-05	0.000214	CcSEcCtD
Paroxetine—Diarrhoea—Etoposide—uterine cancer	8.47e-05	0.000214	CcSEcCtD
Paroxetine—Eye disorder—Doxorubicin—uterine cancer	8.44e-05	0.000213	CcSEcCtD
Paroxetine—Tinnitus—Doxorubicin—uterine cancer	8.42e-05	0.000213	CcSEcCtD
Paroxetine—Flushing—Doxorubicin—uterine cancer	8.38e-05	0.000212	CcSEcCtD
Paroxetine—Cardiac disorder—Doxorubicin—uterine cancer	8.38e-05	0.000212	CcSEcCtD
Paroxetine—Flatulence—Epirubicin—uterine cancer	8.38e-05	0.000211	CcSEcCtD
Paroxetine—Tension—Epirubicin—uterine cancer	8.34e-05	0.00021	CcSEcCtD
Paroxetine—Dysgeusia—Epirubicin—uterine cancer	8.32e-05	0.00021	CcSEcCtD
Paroxetine—Nervousness—Epirubicin—uterine cancer	8.26e-05	0.000208	CcSEcCtD
Paroxetine—Back pain—Epirubicin—uterine cancer	8.22e-05	0.000207	CcSEcCtD
Paroxetine—Angiopathy—Doxorubicin—uterine cancer	8.2e-05	0.000207	CcSEcCtD
Paroxetine—Dizziness—Etoposide—uterine cancer	8.18e-05	0.000206	CcSEcCtD
Paroxetine—Muscle spasms—Epirubicin—uterine cancer	8.17e-05	0.000206	CcSEcCtD
Paroxetine—Immune system disorder—Doxorubicin—uterine cancer	8.16e-05	0.000206	CcSEcCtD
Paroxetine—Mediastinal disorder—Doxorubicin—uterine cancer	8.14e-05	0.000205	CcSEcCtD
Paroxetine—Chills—Doxorubicin—uterine cancer	8.11e-05	0.000205	CcSEcCtD
Paroxetine—Arrhythmia—Doxorubicin—uterine cancer	8.07e-05	0.000204	CcSEcCtD
Paroxetine—Vision blurred—Epirubicin—uterine cancer	8.01e-05	0.000202	CcSEcCtD
Paroxetine—Alopecia—Doxorubicin—uterine cancer	7.98e-05	0.000201	CcSEcCtD
Paroxetine—Mental disorder—Doxorubicin—uterine cancer	7.92e-05	0.0002	CcSEcCtD
Paroxetine—Ill-defined disorder—Epirubicin—uterine cancer	7.89e-05	0.000199	CcSEcCtD
Paroxetine—Vomiting—Etoposide—uterine cancer	7.87e-05	0.000199	CcSEcCtD
Paroxetine—Erythema—Doxorubicin—uterine cancer	7.86e-05	0.000198	CcSEcCtD
Paroxetine—Malnutrition—Doxorubicin—uterine cancer	7.86e-05	0.000198	CcSEcCtD
Paroxetine—Anaemia—Epirubicin—uterine cancer	7.86e-05	0.000198	CcSEcCtD
Paroxetine—Agitation—Epirubicin—uterine cancer	7.81e-05	0.000197	CcSEcCtD
Paroxetine—Rash—Etoposide—uterine cancer	7.8e-05	0.000197	CcSEcCtD
Paroxetine—Dermatitis—Etoposide—uterine cancer	7.8e-05	0.000197	CcSEcCtD
Paroxetine—Headache—Etoposide—uterine cancer	7.75e-05	0.000196	CcSEcCtD
Paroxetine—Flatulence—Doxorubicin—uterine cancer	7.75e-05	0.000196	CcSEcCtD
Paroxetine—Tension—Doxorubicin—uterine cancer	7.72e-05	0.000195	CcSEcCtD
Paroxetine—Dysgeusia—Doxorubicin—uterine cancer	7.7e-05	0.000194	CcSEcCtD
Paroxetine—Malaise—Epirubicin—uterine cancer	7.67e-05	0.000193	CcSEcCtD
Paroxetine—Nervousness—Doxorubicin—uterine cancer	7.64e-05	0.000193	CcSEcCtD
Paroxetine—Vertigo—Epirubicin—uterine cancer	7.64e-05	0.000193	CcSEcCtD
Paroxetine—Syncope—Epirubicin—uterine cancer	7.62e-05	0.000192	CcSEcCtD
Paroxetine—Leukopenia—Epirubicin—uterine cancer	7.61e-05	0.000192	CcSEcCtD
Paroxetine—Back pain—Doxorubicin—uterine cancer	7.61e-05	0.000192	CcSEcCtD
Paroxetine—Muscle spasms—Doxorubicin—uterine cancer	7.56e-05	0.000191	CcSEcCtD
Paroxetine—Palpitations—Epirubicin—uterine cancer	7.51e-05	0.000189	CcSEcCtD
Paroxetine—Loss of consciousness—Epirubicin—uterine cancer	7.47e-05	0.000188	CcSEcCtD
Paroxetine—Cough—Epirubicin—uterine cancer	7.42e-05	0.000187	CcSEcCtD
Paroxetine—Vision blurred—Doxorubicin—uterine cancer	7.41e-05	0.000187	CcSEcCtD
Paroxetine—Convulsion—Epirubicin—uterine cancer	7.36e-05	0.000186	CcSEcCtD
Paroxetine—Nausea—Etoposide—uterine cancer	7.35e-05	0.000185	CcSEcCtD
Paroxetine—Hypertension—Epirubicin—uterine cancer	7.34e-05	0.000185	CcSEcCtD
Paroxetine—Ill-defined disorder—Doxorubicin—uterine cancer	7.3e-05	0.000184	CcSEcCtD
Paroxetine—Anaemia—Doxorubicin—uterine cancer	7.27e-05	0.000183	CcSEcCtD
Paroxetine—Chest pain—Epirubicin—uterine cancer	7.24e-05	0.000183	CcSEcCtD
Paroxetine—Arthralgia—Epirubicin—uterine cancer	7.24e-05	0.000183	CcSEcCtD
Paroxetine—Myalgia—Epirubicin—uterine cancer	7.24e-05	0.000183	CcSEcCtD
Paroxetine—Agitation—Doxorubicin—uterine cancer	7.23e-05	0.000182	CcSEcCtD
Paroxetine—Anxiety—Epirubicin—uterine cancer	7.21e-05	0.000182	CcSEcCtD
Paroxetine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—uterine cancer	7.19e-05	0.000181	CcSEcCtD
Paroxetine—Discomfort—Epirubicin—uterine cancer	7.15e-05	0.00018	CcSEcCtD
Paroxetine—Malaise—Doxorubicin—uterine cancer	7.09e-05	0.000179	CcSEcCtD
Paroxetine—Dry mouth—Epirubicin—uterine cancer	7.08e-05	0.000179	CcSEcCtD
Paroxetine—Vertigo—Doxorubicin—uterine cancer	7.07e-05	0.000178	CcSEcCtD
Paroxetine—Syncope—Doxorubicin—uterine cancer	7.05e-05	0.000178	CcSEcCtD
Paroxetine—Leukopenia—Doxorubicin—uterine cancer	7.04e-05	0.000178	CcSEcCtD
Paroxetine—Confusional state—Epirubicin—uterine cancer	6.99e-05	0.000176	CcSEcCtD
Paroxetine—Palpitations—Doxorubicin—uterine cancer	6.95e-05	0.000175	CcSEcCtD
Paroxetine—Anaphylactic shock—Epirubicin—uterine cancer	6.94e-05	0.000175	CcSEcCtD
Paroxetine—Oedema—Epirubicin—uterine cancer	6.94e-05	0.000175	CcSEcCtD
Paroxetine—Loss of consciousness—Doxorubicin—uterine cancer	6.91e-05	0.000174	CcSEcCtD
Paroxetine—Infection—Epirubicin—uterine cancer	6.89e-05	0.000174	CcSEcCtD
Paroxetine—Cough—Doxorubicin—uterine cancer	6.86e-05	0.000173	CcSEcCtD
Paroxetine—Shock—Epirubicin—uterine cancer	6.82e-05	0.000172	CcSEcCtD
Paroxetine—Convulsion—Doxorubicin—uterine cancer	6.81e-05	0.000172	CcSEcCtD
Paroxetine—Nervous system disorder—Epirubicin—uterine cancer	6.8e-05	0.000172	CcSEcCtD
Paroxetine—Thrombocytopenia—Epirubicin—uterine cancer	6.79e-05	0.000171	CcSEcCtD
Paroxetine—Hypertension—Doxorubicin—uterine cancer	6.79e-05	0.000171	CcSEcCtD
Paroxetine—Tachycardia—Epirubicin—uterine cancer	6.77e-05	0.000171	CcSEcCtD
Paroxetine—Skin disorder—Epirubicin—uterine cancer	6.74e-05	0.00017	CcSEcCtD
Paroxetine—Hyperhidrosis—Epirubicin—uterine cancer	6.71e-05	0.000169	CcSEcCtD
Paroxetine—Arthralgia—Doxorubicin—uterine cancer	6.7e-05	0.000169	CcSEcCtD
Paroxetine—Chest pain—Doxorubicin—uterine cancer	6.7e-05	0.000169	CcSEcCtD
Paroxetine—Myalgia—Doxorubicin—uterine cancer	6.7e-05	0.000169	CcSEcCtD
Paroxetine—Anxiety—Doxorubicin—uterine cancer	6.67e-05	0.000168	CcSEcCtD
Paroxetine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—uterine cancer	6.65e-05	0.000168	CcSEcCtD
Paroxetine—Discomfort—Doxorubicin—uterine cancer	6.62e-05	0.000167	CcSEcCtD
Paroxetine—Dry mouth—Doxorubicin—uterine cancer	6.55e-05	0.000165	CcSEcCtD
Paroxetine—Hypotension—Epirubicin—uterine cancer	6.48e-05	0.000164	CcSEcCtD
Paroxetine—Confusional state—Doxorubicin—uterine cancer	6.47e-05	0.000163	CcSEcCtD
Paroxetine—Oedema—Doxorubicin—uterine cancer	6.42e-05	0.000162	CcSEcCtD
Paroxetine—Anaphylactic shock—Doxorubicin—uterine cancer	6.42e-05	0.000162	CcSEcCtD
Paroxetine—Infection—Doxorubicin—uterine cancer	6.38e-05	0.000161	CcSEcCtD
Paroxetine—Musculoskeletal discomfort—Epirubicin—uterine cancer	6.32e-05	0.000159	CcSEcCtD
Paroxetine—Shock—Doxorubicin—uterine cancer	6.31e-05	0.000159	CcSEcCtD
Paroxetine—Nervous system disorder—Doxorubicin—uterine cancer	6.29e-05	0.000159	CcSEcCtD
Paroxetine—Thrombocytopenia—Doxorubicin—uterine cancer	6.28e-05	0.000159	CcSEcCtD
Paroxetine—Insomnia—Epirubicin—uterine cancer	6.27e-05	0.000158	CcSEcCtD
Paroxetine—Tachycardia—Doxorubicin—uterine cancer	6.26e-05	0.000158	CcSEcCtD
Paroxetine—Skin disorder—Doxorubicin—uterine cancer	6.23e-05	0.000157	CcSEcCtD
Paroxetine—Paraesthesia—Epirubicin—uterine cancer	6.23e-05	0.000157	CcSEcCtD
Paroxetine—Hyperhidrosis—Doxorubicin—uterine cancer	6.21e-05	0.000157	CcSEcCtD
Paroxetine—Dyspnoea—Epirubicin—uterine cancer	6.18e-05	0.000156	CcSEcCtD
Paroxetine—Somnolence—Epirubicin—uterine cancer	6.17e-05	0.000156	CcSEcCtD
Paroxetine—Dyspepsia—Epirubicin—uterine cancer	6.11e-05	0.000154	CcSEcCtD
Paroxetine—Decreased appetite—Epirubicin—uterine cancer	6.03e-05	0.000152	CcSEcCtD
Paroxetine—Hypotension—Doxorubicin—uterine cancer	6e-05	0.000151	CcSEcCtD
Paroxetine—Gastrointestinal disorder—Epirubicin—uterine cancer	5.99e-05	0.000151	CcSEcCtD
Paroxetine—Fatigue—Epirubicin—uterine cancer	5.98e-05	0.000151	CcSEcCtD
Paroxetine—Pain—Epirubicin—uterine cancer	5.93e-05	0.00015	CcSEcCtD
Paroxetine—Constipation—Epirubicin—uterine cancer	5.93e-05	0.00015	CcSEcCtD
Paroxetine—Musculoskeletal discomfort—Doxorubicin—uterine cancer	5.85e-05	0.000148	CcSEcCtD
Paroxetine—Insomnia—Doxorubicin—uterine cancer	5.81e-05	0.000146	CcSEcCtD
Paroxetine—Paraesthesia—Doxorubicin—uterine cancer	5.76e-05	0.000145	CcSEcCtD
Paroxetine—Dyspnoea—Doxorubicin—uterine cancer	5.72e-05	0.000144	CcSEcCtD
Paroxetine—Feeling abnormal—Epirubicin—uterine cancer	5.72e-05	0.000144	CcSEcCtD
Paroxetine—Somnolence—Doxorubicin—uterine cancer	5.71e-05	0.000144	CcSEcCtD
Paroxetine—Gastrointestinal pain—Epirubicin—uterine cancer	5.67e-05	0.000143	CcSEcCtD
Paroxetine—Dyspepsia—Doxorubicin—uterine cancer	5.65e-05	0.000143	CcSEcCtD
Paroxetine—Decreased appetite—Doxorubicin—uterine cancer	5.58e-05	0.000141	CcSEcCtD
Paroxetine—Gastrointestinal disorder—Doxorubicin—uterine cancer	5.54e-05	0.00014	CcSEcCtD
Paroxetine—Fatigue—Doxorubicin—uterine cancer	5.53e-05	0.00014	CcSEcCtD
Paroxetine—Urticaria—Epirubicin—uterine cancer	5.51e-05	0.000139	CcSEcCtD
Paroxetine—Constipation—Doxorubicin—uterine cancer	5.49e-05	0.000138	CcSEcCtD
Paroxetine—Pain—Doxorubicin—uterine cancer	5.49e-05	0.000138	CcSEcCtD
Paroxetine—Body temperature increased—Epirubicin—uterine cancer	5.48e-05	0.000138	CcSEcCtD
Paroxetine—Abdominal pain—Epirubicin—uterine cancer	5.48e-05	0.000138	CcSEcCtD
Paroxetine—Feeling abnormal—Doxorubicin—uterine cancer	5.29e-05	0.000133	CcSEcCtD
Paroxetine—Gastrointestinal pain—Doxorubicin—uterine cancer	5.25e-05	0.000132	CcSEcCtD
Paroxetine—Hypersensitivity—Epirubicin—uterine cancer	5.11e-05	0.000129	CcSEcCtD
Paroxetine—Urticaria—Doxorubicin—uterine cancer	5.1e-05	0.000129	CcSEcCtD
Paroxetine—Abdominal pain—Doxorubicin—uterine cancer	5.07e-05	0.000128	CcSEcCtD
Paroxetine—Body temperature increased—Doxorubicin—uterine cancer	5.07e-05	0.000128	CcSEcCtD
Paroxetine—Asthenia—Epirubicin—uterine cancer	4.98e-05	0.000126	CcSEcCtD
Paroxetine—Pruritus—Epirubicin—uterine cancer	4.91e-05	0.000124	CcSEcCtD
Paroxetine—Diarrhoea—Epirubicin—uterine cancer	4.75e-05	0.00012	CcSEcCtD
Paroxetine—Hypersensitivity—Doxorubicin—uterine cancer	4.73e-05	0.000119	CcSEcCtD
Paroxetine—Asthenia—Doxorubicin—uterine cancer	4.61e-05	0.000116	CcSEcCtD
Paroxetine—Dizziness—Epirubicin—uterine cancer	4.59e-05	0.000116	CcSEcCtD
Paroxetine—Pruritus—Doxorubicin—uterine cancer	4.54e-05	0.000115	CcSEcCtD
Paroxetine—Vomiting—Epirubicin—uterine cancer	4.41e-05	0.000111	CcSEcCtD
Paroxetine—Diarrhoea—Doxorubicin—uterine cancer	4.39e-05	0.000111	CcSEcCtD
Paroxetine—Rash—Epirubicin—uterine cancer	4.37e-05	0.00011	CcSEcCtD
Paroxetine—Dermatitis—Epirubicin—uterine cancer	4.37e-05	0.00011	CcSEcCtD
Paroxetine—Headache—Epirubicin—uterine cancer	4.35e-05	0.00011	CcSEcCtD
Paroxetine—Dizziness—Doxorubicin—uterine cancer	4.24e-05	0.000107	CcSEcCtD
Paroxetine—Nausea—Epirubicin—uterine cancer	4.12e-05	0.000104	CcSEcCtD
Paroxetine—Vomiting—Doxorubicin—uterine cancer	4.08e-05	0.000103	CcSEcCtD
Paroxetine—Rash—Doxorubicin—uterine cancer	4.05e-05	0.000102	CcSEcCtD
Paroxetine—Dermatitis—Doxorubicin—uterine cancer	4.04e-05	0.000102	CcSEcCtD
Paroxetine—Headache—Doxorubicin—uterine cancer	4.02e-05	0.000101	CcSEcCtD
Paroxetine—Nausea—Doxorubicin—uterine cancer	3.81e-05	9.62e-05	CcSEcCtD
Paroxetine—CHRM3—Metabolism—STK11—uterine cancer	1.72e-06	0.000545	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—CYP19A1—uterine cancer	1.72e-06	0.000545	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—YWHAE—uterine cancer	1.72e-06	0.000544	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—AKR1C1—uterine cancer	1.72e-06	0.000544	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—CYP11A1—uterine cancer	1.7e-06	0.00054	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—AKR1C1—uterine cancer	1.7e-06	0.000539	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—YWHAE—uterine cancer	1.7e-06	0.000539	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—CXCL8—uterine cancer	1.69e-06	0.000534	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—SMAD3—uterine cancer	1.68e-06	0.000532	CbGpPWpGaD
Paroxetine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—uterine cancer	1.68e-06	0.000531	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—FGFR2—uterine cancer	1.67e-06	0.00053	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—FBXW7—uterine cancer	1.66e-06	0.000526	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—FBXW7—uterine cancer	1.65e-06	0.000523	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—FBXW7—uterine cancer	1.65e-06	0.000522	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—FBXW7—uterine cancer	1.63e-06	0.000517	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—RRM2—uterine cancer	1.62e-06	0.000514	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—CXCL8—uterine cancer	1.61e-06	0.000511	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—AKR1C3—uterine cancer	1.61e-06	0.00051	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—FGFR2—uterine cancer	1.6e-06	0.000507	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—DCN—uterine cancer	1.58e-06	0.000499	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—RRM2—uterine cancer	1.53e-06	0.000485	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—RRM2—uterine cancer	1.52e-06	0.00048	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—KRAS—uterine cancer	1.5e-06	0.000474	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—DCN—uterine cancer	1.49e-06	0.00047	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—CYP11A1—uterine cancer	1.49e-06	0.00047	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—STK11—uterine cancer	1.48e-06	0.000469	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—CYP19A1—uterine cancer	1.48e-06	0.000469	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—DCN—uterine cancer	1.47e-06	0.000466	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—STK11—uterine cancer	1.45e-06	0.00046	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—CCL2—uterine cancer	1.45e-06	0.000458	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—STK11—uterine cancer	1.44e-06	0.000457	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—STK11—uterine cancer	1.44e-06	0.000456	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—CCL2—uterine cancer	1.44e-06	0.000455	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—CCL2—uterine cancer	1.43e-06	0.000454	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—ESR1—uterine cancer	1.43e-06	0.000453	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—STK11—uterine cancer	1.43e-06	0.000452	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—CCL2—uterine cancer	1.42e-06	0.000449	CbGpPWpGaD
Paroxetine—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—uterine cancer	1.42e-06	0.000448	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—AKR1C3—uterine cancer	1.4e-06	0.000444	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—CYP11A1—uterine cancer	1.4e-06	0.000443	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—CYP11A1—uterine cancer	1.39e-06	0.000439	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—PIK3CA—uterine cancer	1.38e-06	0.000436	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—ESR1—uterine cancer	1.37e-06	0.000434	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—SOCS3—uterine cancer	1.36e-06	0.000431	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—SOCS3—uterine cancer	1.35e-06	0.000428	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—NRAS—uterine cancer	1.35e-06	0.000428	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—SOCS3—uterine cancer	1.35e-06	0.000427	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—SOCS3—uterine cancer	1.34e-06	0.000423	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—TP53—uterine cancer	1.33e-06	0.000422	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—AKR1C3—uterine cancer	1.32e-06	0.000419	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—AKR1C3—uterine cancer	1.31e-06	0.000415	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—CDKN2B—uterine cancer	1.3e-06	0.000412	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—NRAS—uterine cancer	1.3e-06	0.00041	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—CDKN2B—uterine cancer	1.29e-06	0.00041	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—MTHFR—uterine cancer	1.29e-06	0.00041	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—CDKN2B—uterine cancer	1.29e-06	0.000409	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—CDKN2B—uterine cancer	1.28e-06	0.000405	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—HRAS—uterine cancer	1.27e-06	0.000403	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—IGF1R—uterine cancer	1.26e-06	0.0004	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—CCL2—uterine cancer	1.26e-06	0.000399	CbGpPWpGaD
Paroxetine—HTR2A—GPCR downstream signaling—CXCL8—uterine cancer	1.26e-06	0.000399	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—IGF1R—uterine cancer	1.26e-06	0.000398	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—STK11—uterine cancer	1.25e-06	0.000397	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—CYP19A1—uterine cancer	1.25e-06	0.000397	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—IGF1R—uterine cancer	1.25e-06	0.000397	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—CXCL8—uterine cancer	1.25e-06	0.000396	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—CXCL8—uterine cancer	1.25e-06	0.000395	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—IGF1R—uterine cancer	1.24e-06	0.000393	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—CXCL8—uterine cancer	1.24e-06	0.000391	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—CCL2—uterine cancer	1.21e-06	0.000382	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—SMAD3—uterine cancer	1.19e-06	0.000376	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—SMAD3—uterine cancer	1.18e-06	0.000374	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—SMAD3—uterine cancer	1.18e-06	0.000373	CbGpPWpGaD
Paroxetine—CHRM4—GPCR downstream signaling—PIK3CA—uterine cancer	1.18e-06	0.000373	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	1.18e-06	0.000373	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—SMAD3—uterine cancer	1.17e-06	0.00037	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—KRAS—uterine cancer	1.16e-06	0.000369	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—CXCL8—uterine cancer	1.14e-06	0.000362	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—CXCL8—uterine cancer	1.14e-06	0.00036	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—FGFR2—uterine cancer	1.13e-06	0.000359	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—CXCL8—uterine cancer	1.13e-06	0.000359	CbGpPWpGaD
Paroxetine—CHRM5—GPCR downstream signaling—PIK3CA—uterine cancer	1.13e-06	0.000357	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—FGFR2—uterine cancer	1.13e-06	0.000357	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—FGFR2—uterine cancer	1.12e-06	0.000356	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—AKT1—uterine cancer	1.12e-06	0.000356	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism of lipids and lipoproteins—EP300—uterine cancer	1.12e-06	0.000356	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—CXCL8—uterine cancer	1.12e-06	0.000355	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—KRAS—uterine cancer	1.11e-06	0.000353	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—MTHFR—uterine cancer	1.11e-06	0.000353	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—FGFR2—uterine cancer	1.11e-06	0.000352	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—STK11—uterine cancer	1.09e-06	0.000346	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—CYP19A1—uterine cancer	1.09e-06	0.000346	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—PIK3CA—uterine cancer	1.07e-06	0.000339	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—ERBB2—uterine cancer	1.05e-06	0.000333	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—STK11—uterine cancer	1.03e-06	0.000326	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—CYP19A1—uterine cancer	1.03e-06	0.000326	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—PIK3CA—uterine cancer	1.02e-06	0.000324	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—CYP19A1—uterine cancer	1.02e-06	0.000323	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—STK11—uterine cancer	1.02e-06	0.000323	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—ERBB2—uterine cancer	1.01e-06	0.000318	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—CXCL8—uterine cancer	9.96e-07	0.000315	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—HRAS—uterine cancer	9.89e-07	0.000313	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—CDKN1B—uterine cancer	9.73e-07	0.000308	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—ESR1—uterine cancer	9.7e-07	0.000307	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—ESR1—uterine cancer	9.65e-07	0.000306	CbGpPWpGaD
Paroxetine—CHRM4—GPCR downstream signaling—AKT1—uterine cancer	9.62e-07	0.000305	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—ESR1—uterine cancer	9.62e-07	0.000305	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	9.58e-07	0.000303	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—CXCL8—uterine cancer	9.54e-07	0.000302	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—ESR1—uterine cancer	9.52e-07	0.000302	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—HRAS—uterine cancer	9.48e-07	0.0003	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—MTHFR—uterine cancer	9.42e-07	0.000298	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—CDKN1B—uterine cancer	9.31e-07	0.000295	CbGpPWpGaD
Paroxetine—CHRM5—GPCR downstream signaling—AKT1—uterine cancer	9.21e-07	0.000292	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—CTNNB1—uterine cancer	9.19e-07	0.000291	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—NRAS—uterine cancer	9.17e-07	0.00029	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism of lipids and lipoproteins—EP300—uterine cancer	9.14e-07	0.000289	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—NRAS—uterine cancer	9.12e-07	0.000289	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—NRAS—uterine cancer	9.09e-07	0.000288	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—NRAS—uterine cancer	9e-07	0.000285	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—PTEN—uterine cancer	8.96e-07	0.000284	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—CTNNB1—uterine cancer	8.8e-07	0.000279	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—AKT1—uterine cancer	8.74e-07	0.000277	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—PTEN—uterine cancer	8.58e-07	0.000272	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—EP300—uterine cancer	8.54e-07	0.00027	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—CCL2—uterine cancer	8.54e-07	0.00027	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—CCL2—uterine cancer	8.49e-07	0.000269	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—CCL2—uterine cancer	8.47e-07	0.000268	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—CCL2—uterine cancer	8.38e-07	0.000266	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—AKT1—uterine cancer	8.37e-07	0.000265	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	8.3e-07	0.000263	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—MTHFR—uterine cancer	8.21e-07	0.00026	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—EP300—uterine cancer	8.18e-07	0.000259	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—VEGFA—uterine cancer	8.09e-07	0.000256	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—NRAS—uterine cancer	7.99e-07	0.000253	CbGpPWpGaD
Paroxetine—HTR2A—GPCR downstream signaling—PIK3CA—uterine cancer	7.98e-07	0.000253	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—PIK3CA—uterine cancer	7.94e-07	0.000251	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—PIK3CA—uterine cancer	7.92e-07	0.000251	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—KRAS—uterine cancer	7.89e-07	0.00025	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—KRAS—uterine cancer	7.85e-07	0.000249	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—PIK3CA—uterine cancer	7.84e-07	0.000248	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—KRAS—uterine cancer	7.82e-07	0.000248	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—KRAS—uterine cancer	7.75e-07	0.000245	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—VEGFA—uterine cancer	7.75e-07	0.000245	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—MTHFR—uterine cancer	7.74e-07	0.000245	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—MTHFR—uterine cancer	7.67e-07	0.000243	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—NRAS—uterine cancer	7.65e-07	0.000242	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—PIK3CA—uterine cancer	7.25e-07	0.00023	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—PIK3CA—uterine cancer	7.21e-07	0.000228	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—PTEN—uterine cancer	7.2e-07	0.000228	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—PIK3CA—uterine cancer	7.19e-07	0.000228	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—ERBB2—uterine cancer	7.12e-07	0.000225	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—PIK3CA—uterine cancer	7.12e-07	0.000225	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—ERBB2—uterine cancer	7.08e-07	0.000224	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—ERBB2—uterine cancer	7.06e-07	0.000224	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—ERBB2—uterine cancer	6.99e-07	0.000221	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—KRAS—uterine cancer	6.88e-07	0.000218	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—EP300—uterine cancer	6.86e-07	0.000217	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	6.76e-07	0.000214	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—CXCL8—uterine cancer	6.75e-07	0.000214	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—CXCL8—uterine cancer	6.72e-07	0.000213	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—HRAS—uterine cancer	6.71e-07	0.000212	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—CXCL8—uterine cancer	6.69e-07	0.000212	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—HRAS—uterine cancer	6.67e-07	0.000211	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—HRAS—uterine cancer	6.65e-07	0.000211	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—CXCL8—uterine cancer	6.63e-07	0.00021	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—CDKN1B—uterine cancer	6.59e-07	0.000209	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—HRAS—uterine cancer	6.59e-07	0.000209	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—KRAS—uterine cancer	6.59e-07	0.000209	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—CDKN1B—uterine cancer	6.56e-07	0.000208	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—CDKN1B—uterine cancer	6.54e-07	0.000207	CbGpPWpGaD
Paroxetine—HTR2A—GPCR downstream signaling—AKT1—uterine cancer	6.52e-07	0.000207	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—AKT1—uterine cancer	6.49e-07	0.000205	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—CDKN1B—uterine cancer	6.47e-07	0.000205	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—AKT1—uterine cancer	6.47e-07	0.000205	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—AKT1—uterine cancer	6.4e-07	0.000203	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—PIK3CA—uterine cancer	6.32e-07	0.0002	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—CTNNB1—uterine cancer	6.23e-07	0.000197	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—CTNNB1—uterine cancer	6.2e-07	0.000196	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—PTEN—uterine cancer	6.19e-07	0.000196	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—CTNNB1—uterine cancer	6.18e-07	0.000196	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—CTNNB1—uterine cancer	6.12e-07	0.000194	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—TP53—uterine cancer	6.11e-07	0.000194	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—PTEN—uterine cancer	6.07e-07	0.000192	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—PIK3CA—uterine cancer	6.05e-07	0.000192	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—PTEN—uterine cancer	6.04e-07	0.000191	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—PTEN—uterine cancer	6.02e-07	0.000191	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—PTEN—uterine cancer	5.96e-07	0.000189	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—AKT1—uterine cancer	5.92e-07	0.000188	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—EP300—uterine cancer	5.91e-07	0.000187	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—AKT1—uterine cancer	5.89e-07	0.000187	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—AKT1—uterine cancer	5.87e-07	0.000186	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—TP53—uterine cancer	5.85e-07	0.000185	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—HRAS—uterine cancer	5.84e-07	0.000185	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—AKT1—uterine cancer	5.82e-07	0.000184	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—EP300—uterine cancer	5.79e-07	0.000183	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—EP300—uterine cancer	5.76e-07	0.000182	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—EP300—uterine cancer	5.74e-07	0.000182	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—EP300—uterine cancer	5.68e-07	0.00018	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—HRAS—uterine cancer	5.6e-07	0.000177	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—VEGFA—uterine cancer	5.48e-07	0.000174	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—VEGFA—uterine cancer	5.45e-07	0.000173	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—VEGFA—uterine cancer	5.44e-07	0.000172	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—NRAS—uterine cancer	5.42e-07	0.000172	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—NRAS—uterine cancer	5.39e-07	0.000171	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—VEGFA—uterine cancer	5.38e-07	0.00017	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—NRAS—uterine cancer	5.37e-07	0.00017	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—NRAS—uterine cancer	5.32e-07	0.000168	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—PTEN—uterine cancer	5.24e-07	0.000166	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—AKT1—uterine cancer	5.16e-07	0.000163	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—PIK3CA—uterine cancer	5.08e-07	0.000161	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—EP300—uterine cancer	5e-07	0.000158	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—AKT1—uterine cancer	4.94e-07	0.000157	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—KRAS—uterine cancer	4.66e-07	0.000148	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—KRAS—uterine cancer	4.64e-07	0.000147	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—KRAS—uterine cancer	4.62e-07	0.000146	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—KRAS—uterine cancer	4.58e-07	0.000145	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—PTEN—uterine cancer	4.57e-07	0.000145	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—PIK3CA—uterine cancer	4.37e-07	0.000138	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—EP300—uterine cancer	4.36e-07	0.000138	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—PTEN—uterine cancer	4.3e-07	0.000136	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—PIK3CA—uterine cancer	4.28e-07	0.000136	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—PTEN—uterine cancer	4.27e-07	0.000135	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—PIK3CA—uterine cancer	4.26e-07	0.000135	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—PIK3CA—uterine cancer	4.25e-07	0.000134	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—PIK3CA—uterine cancer	4.21e-07	0.000133	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—AKT1—uterine cancer	4.15e-07	0.000131	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—TP53—uterine cancer	4.14e-07	0.000131	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—TP53—uterine cancer	4.12e-07	0.000131	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—TP53—uterine cancer	4.11e-07	0.00013	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—EP300—uterine cancer	4.1e-07	0.00013	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—EP300—uterine cancer	4.07e-07	0.000129	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—TP53—uterine cancer	4.07e-07	0.000129	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—HRAS—uterine cancer	3.96e-07	0.000125	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—HRAS—uterine cancer	3.94e-07	0.000125	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—HRAS—uterine cancer	3.93e-07	0.000124	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—HRAS—uterine cancer	3.89e-07	0.000123	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—PIK3CA—uterine cancer	3.7e-07	0.000117	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—AKT1—uterine cancer	3.57e-07	0.000113	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—AKT1—uterine cancer	3.5e-07	0.000111	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—AKT1—uterine cancer	3.48e-07	0.00011	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—AKT1—uterine cancer	3.47e-07	0.00011	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—AKT1—uterine cancer	3.44e-07	0.000109	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—PIK3CA—uterine cancer	3.22e-07	0.000102	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—PIK3CA—uterine cancer	3.04e-07	9.62e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—AKT1—uterine cancer	3.02e-07	9.57e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—PIK3CA—uterine cancer	3.01e-07	9.53e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—AKT1—uterine cancer	2.63e-07	8.34e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—AKT1—uterine cancer	2.48e-07	7.86e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—AKT1—uterine cancer	2.46e-07	7.79e-05	CbGpPWpGaD
